The FDA issued updates on October 24 regarding drugs that are currently in shortage:
- Bleomycin Sulfate for Injection (Updated – Currently in Shortage)
- Carbidopa and Levodopa Extended Release Tablets (Updated – Currently in Shortage)
- Dextrose 5% Injection Bags (Updated – Currently in Shortage)
- Folic Acid Injection (Updated – Currently in Shortage)
- Imipenem and Cilastatin for Injection, USP (Updated – Currently in Shortage)
- Lidocaine Hydrochloride (Xylocaine) Injection (Updated – Currently in Shortage)
- Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine (Updated – Currently in Shortage)
- Methylprednisolone Sodium Succinate for Injection, USP (Updated – Currently in Shortage)
- Metoclopramide Injection, USP (New – Currently in Shortage)
- Metoclopramide Injection, USP (New – Discontinuation)
- Potassium Chloride Injection (Updated – Currently in Shortage)
- Potassium Phosphate Injection (Updated – Currently in Shortage)
- Rocuronium Bromide Injection (Updated – Currently in Shortage)
- Sodium Bicarbonate Injection, USP (Updated – Currently in Shortage)
- Sodium Chloride 0.9% Injection Bags (Updated – Currently in Shortage)
- Sodium Chloride 23.4% Injection (Updated – Currently in Shortage)
- Sterile Talc Powder (Updated – Currently in Shortage)
According to the FDA:
“A drug receives Resolved status when the Drug Shortages Staff (DSS) determines that the market is covered, based on information from all manufacturers. The market is considered covered when supply is available from at least one manufacturer to cover total market demand. However, some manufacturers may not have all presentations available. DSS monitors the supply of products with Resolved status. For the most current supply information, contact the manufacturers.”
(Source: U.S. Food & Drug Adminstration)
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!